610 filings
Page 10 of 31
8-K
BLPH
Bellerophon Therapeutics, Inc.
20 May 20
Bellerophon Therapeutics Announces Proposed Public Offering of Common Stock
4:04pm
424B5
BLPH
Bellerophon Therapeutics, Inc.
20 May 20
Prospectus supplement for primary offering
4:03pm
424B5
BLPH
Bellerophon Therapeutics, Inc.
20 May 20
Prospectus supplement for primary offering
4:02pm
424B5
BLPH
Bellerophon Therapeutics, Inc.
18 May 20
Prospectus supplement for primary offering
4:02pm
8-K
BLPH
Bellerophon Therapeutics, Inc.
11 May 20
Bellerophon Provides Clinical Program Update and Reports First Quarter 2020 Financial Results
4:03pm
10-Q
2020 Q1
BLPH
Bellerophon Therapeutics, Inc.
Quarterly report
11 May 20
4:01pm
8-K
BLPH
Bellerophon Therapeutics, Inc.
11 May 20
Bellerophon Therapeutics Announces FDA Clears Initiation of Phase 3 Study for INOpulse® Inhaled Nitric Oxide Therapy to Treat COVID-19
8:29am
DEFA14A
BLPH
Bellerophon Therapeutics, Inc.
27 Apr 20
Additional proxy soliciting materials
4:31pm
DEF 14A
BLPH
Bellerophon Therapeutics, Inc.
Definitive proxy
23 Apr 20
8:17am
4
Theodore T Wang
20 Apr 20
Bellerophon Therapeutics / Theodore T Wang ownership change
10:47am
8-K
BLPH
Bellerophon Therapeutics, Inc.
8 Apr 20
Other Events
8:31am
8-K
BLPH
Bellerophon Therapeutics, Inc.
6 Apr 20
Bellerophon Provides Clinical Program Update and Reports Fourth Quarter and Full-Year 2019 Financial Results
8:32am
10-K
2019 FY
BLPH
Bellerophon Therapeutics, Inc.
Annual report
6 Apr 20
8:27am
NT 10-K
BLPH
Bellerophon Therapeutics, Inc.
31 Mar 20
Notice of late annual filing
4:10pm
8-K
BLPH
Bellerophon Therapeutics, Inc.
31 Mar 20
Regulation FD Disclosure
1:28pm
424B5
BLPH
Bellerophon Therapeutics, Inc.
31 Mar 20
Prospectus supplement for primary offering
7:03am
8-K
BLPH
Bellerophon Therapeutics, Inc.
30 Mar 20
Bellerophon Announces $15.3 Million Registered Direct Offering Priced At-the-Market
4:09pm
SC 13G
Sabby Management, LLC
30 Mar 20
Bellerophon Therapeutics / SABBY MANAGEMENT ownership change
10:49am
8-K
BLPH
Bellerophon Therapeutics, Inc.
30 Mar 20
Bellerophon Therapeutics Announces First Patient Treated with INOpulse® Inhaled Nitric Oxide Therapy for COVID-19
8:01am
8-K
BLPH
Bellerophon Therapeutics, Inc.
20 Mar 20
Other Events
8:33am